title: Esmolol administration in patients with VV ECMO: why not?
authors.forename: Federico
authors.initials: F
authors.lastname: Pappalardo
authors.forename: Alberto
authors.initials: A
authors.lastname: Zangrillo
authors.forename: Marina
authors.initials: M
authors.lastname: Pieri
authors.forename: Giovanni
authors.initials: G
authors.lastname: Landoni
authors.forename: Andrea
authors.initials: A
authors.lastname: Morelli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Stefani
authors.forename: Fabio
authors.initials: F
authors.lastname: Guarracino
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy / Q000503:physiopathology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D000075202:Contraindications; D015199:Extracorporeal Membrane Oxygenation; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000860:Hypoxia / Q000209:etiology / Q000628:therapy; D011175:Positive-Pressure Respiration; D011412:Propanolamines / Q000627:therapeutic use*; D018805:Sepsis / Q000150:complications
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C036604:esmolol